NICE backs Sobi’s Kineret for rare inflammatory diseaseThe UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Share XNICE backs Sobi’s Kineret for rare inflammatory diseasehttps://pharmaphorum.com/news/nice-backs-sobis-kineret-for-rare-inflammatory-disease/
Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outRoche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans Share XRoche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outhttps://pharmaphorum.com/news/roches-ulcerative-colitis-drug-etrolizumab-looks-shaky-after-data-roll-out/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
Sanofi’s blockbuster-tipped Dupixent set for European launchesSanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key Share XSanofi’s blockbuster-tipped Dupixent set for European launcheshttps://pharmaphorum.com/news/sanofis-blockbuster-tipped-dupixent-set-european-launches/
